Groupe la Francaise Has $3.92 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Groupe la Francaise boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1,467.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 35,490 shares of the biopharmaceutical company’s stock after buying an additional 33,226 shares during the period. Groupe la Francaise’s holdings in Gilead Sciences were worth $3,918,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank bought a new position in Gilead Sciences during the 2nd quarter worth about $2,150,268,000. Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 135,757 shares of company stock valued at $16,616,127 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research reports. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Rothschild & Co Redburn raised their price target on shares of Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $130.65.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $125.00 on Thursday. The stock has a market capitalization of $155.09 billion, a PE ratio of 19.38, a P/E/G ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The firm has a fifty day simple moving average of $120.53 and a 200 day simple moving average of $115.09. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the company posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.